Incannex Bolsters Clinical Advisory Board with Three Psychiatry Experts

Event summary

  • Incannex Healthcare added three new members to its Clinical Advisory Board on January 29, 2026.
  • New appointees include Murray B. Stein, Andrew Cutler, and Amir Kalali, all experts in psychiatry and clinical development.
  • The board will advise on clinical trial design, endpoint selection, and regulatory strategy for the PSX-001 program.
  • PSX-001 is an oral synthetic psilocybin treatment for generalized anxiety disorder, currently in Phase 2 development.

The big picture

Incannex's expansion of its Clinical Advisory Board underscores the strategic importance of PSX-001, its lead program in synthetic psilocybin for generalized anxiety disorder. The appointments come as the biopharmaceutical industry increasingly leverages external expertise to navigate complex regulatory pathways and optimize clinical trial outcomes. The move also reflects broader trends in mental health innovation, where combination therapies and novel mechanisms are gaining traction. Incannex's ability to execute on this advisory framework will be critical in determining the program's long-term viability and market potential.

What we're watching

Clinical Development
How the new advisory board members will influence the design and execution of PSX-001 clinical trials.
Regulatory Strategy
Whether the board's expertise will accelerate FDA engagement and approval timelines for PSX-001.
Market Positioning
The pace at which Incannex can differentiate PSX-001 in the competitive landscape of anxiety disorder treatments.

Related topics

Mental Health